At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Market Closed 12-12 16:00:00 EST
1.51
-0.15
-9.04%
盘后1.56
+0.05+3.31%
19:52 EST
High1.68Low1.48Vol71.92K
Open1.67D1 Closing1.66Amplitude12.05%
Mkt Cap6.79MTradable Cap5.14MTotal Shares4.50M
T/O113.38KT/O Rate2.11%Tradable Shares3.40M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT
Reuters  ·  12-03
bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT
bioAffinity Technologies Reports Q3 Revenue of $1.5 Million and Net Loss of $5.1 Million
Reuters  ·  11-14
bioAffinity Technologies Reports Q3 Revenue of $1.5 Million and Net Loss of $5.1 Million
bioAffinity Technologies Reports 111% Increase in CyPath Lung Test Volume in October
Reuters  ·  11-05
bioAffinity Technologies Reports 111% Increase in CyPath Lung Test Volume in October
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Lung Disease Diagnostic Platform
Reuters  ·  10-28
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Lung Disease Diagnostic Platform
bioAffinity Technologies Unveils New Research Supporting CyPath Lung Test at CHEST 2025
Reuters  ·  10-20
bioAffinity Technologies Unveils New Research Supporting CyPath Lung Test at CHEST 2025
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains?
Benzinga_recent_news  ·  10-17
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains?
bioAffinity Technologies Receives USPTO Allowance for Patent Covering AI-Based Lung Cancer Diagnostic Test
Reuters  ·  10-16
bioAffinity Technologies Receives USPTO Allowance for Patent Covering AI-Based Lung Cancer Diagnostic Test
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
THOMSON REUTERS  ·  10-16
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
bioAffinity Technologies Regains Nasdaq Compliance, Avoids Delisting After Meeting Listing Standards
Reuters  ·  10-15
bioAffinity Technologies Regains Nasdaq Compliance, Avoids Delisting After Meeting Listing Standards
bioAffinity Technologies Regains Compliance With Nasdaq Listing Requirements
THOMSON REUTERS  ·  10-15
bioAffinity Technologies Regains Compliance With Nasdaq Listing Requirements
Wallachbeth Capital Announces the Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-10
Wallachbeth Capital Announces the Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced at-the-Market Under Nasdaq Rules
bioAffinity Technologies Inc. Announces Date for Upcoming Special Meeting of Stockholders
Reuters  ·  10-09
bioAffinity Technologies Inc. Announces Date for Upcoming Special Meeting of Stockholders
BRIEF-Wallachbeth Capital Announces Bioaffinity Technologies
Reuters  ·  10-09
BRIEF-Wallachbeth Capital Announces Bioaffinity Technologies
BioAffinity Technologies announces $1.8M registered direct offering
TIPRANKS  ·  10-09
BioAffinity Technologies announces $1.8M registered direct offering
bioAffinity Technologies announces 18 million registered direct offering of common stock to support CyPath Lung sales and working capital
Reuters  ·  10-09
bioAffinity Technologies announces 18 million registered direct offering of common stock to support CyPath Lung sales and working capital
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-09
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced at-the-Market Under Nasdaq Rules
What's Driving bioAffinity Technologies' Big Pre-Market Surge?
Benzinga  ·  10-08
What's Driving bioAffinity Technologies' Big Pre-Market Surge?
bioAffinity Technologies reports record growth in CyPath Lung test sales in third quarter 2025
Reuters  ·  10-07
bioAffinity Technologies reports record growth in CyPath Lung test sales in third quarter 2025
BRIEF-Wallachbeth Capital announces pricing of Bioaffinity Technologies public offering for $4.8 mln
Reuters  ·  09-30
BRIEF-Wallachbeth Capital announces pricing of Bioaffinity Technologies public offering for $4.8 mln
Wallachbeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8M
THOMSON REUTERS  ·  09-30
Wallachbeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8M

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--